Esteemed veterinary cardiologist and researcher Dr. Joshua Stern appointed to the TriviumVet Scientific Advisory Board.
TriviumVet™, an animal health research and development company focused on addressing unmet needs in companion animal medicine, today announced that esteemed veterinary cardiologist and researcher Dr. Joshua Stern has been appointed to their Scientific Advisory Board. Dr. Stern is a world leader in translational cardiology and cardiovascular genetic research. He is a Professor of Cardiology and Associate Dean for Veterinary Medical Center Operations at the University of California Davis School of Veterinary Medicine. His active laboratory is dedicated to the pursuit of genetic discovery and investigation of novel therapies for cardiovascular disease. He earned his DVM at the Ohio State University, followed by board certification in cardiology from North Carolina State University and a PhD in Cardiovascular Genetics from Washington State University.
TriviumVet CEO (Chief Executive Officer) Louise Grubb comments “I am delighted to welcome Dr. Stern to our scientific advisory board and want to express my appreciation for his continued scientific contributions as we progress our novel cardiac therapeutics for small animals toward regulatory approval.” Of the Scientific Advisory Board Louise Grubb further comments “We are honoured to have on our Scientific Advisory Board leading scientists and researchers contributing to and shaping our development and clinical programs.” Dr. Stern comments of the appointment “Trivium is working to fill critical needs in veterinary cardiac care. It's an honor to join this talented team as they aim to redefine the standard of care for common and otherwise devastating heart disease in cats and dogs.” Dr. Stern joins fellow Scientific Advisory Board members Dr. Carolyn Henry, Dr. Katie Tolbert, and Dr. Matt Kaeberlein.
Feline Hypertrophic Cardiomyopathy
In addition to his role as Scientific Advisory Board Member Dr. Stern is also the lead investigator in a UC Davis, NCSU and TriviumVet™ clinical study in client-owned cats to evaluate the effectiveness of TriviumVet’s patented, delayed-release rapamycin formulation (Felycin™) in treating hypertrophic cardiomyopathy (HCM). Details of this feline HCM study and its results will be released later this year. The Food and Drug Administration’s Centre for Veterinary Medicine has determined that TriviumVet™ can pursue the expanded conditional approval pathway for Felycin for the treatment of HCM a serious and life-threatening condition that affects approximately 15% of cats and for which there is currently no approved treatment.
TriviumVet company information:
TriviumVet, a veterinary research and development company based in Co. Waterford, Ireland, develops a range of new animal drugs and diagnostics for companion animals. TriviumVet identifies gaps in available treatments and has developed a disruptive and differentiated portfolio with potential to transform existing standards of care in the speciality companion animal markets including cardiology, renal (CKD (chronic kidney disease)), neuropathic pain and gastrointestinal disease. You can read more about the TriviumVet research and development here www.triviumvet.com
Please contact Sarah O’Connor
For a PDF of this press release click here